Key result
Bromocriptine added to GDMT tests for 6-month LVEF improvement in ongoing PPCM trial.
Why the study?
Although evidence suggests bromocriptine may improve outcomes in peripartum cardiomyopathy, no randomized controlled trial has compared bromocriptine with placebo on top of GDMT in a diverse, multiethnic North American cohort.
Does the addition of oral bromocriptine to guideline-directed medical therapy improve left ventricular ejection fraction at 6 months and event-free survival compared to placebo in women with peripartum cardiomyopathy?
RCT (n=250)
Placebo-controlled
Randomized
Does the addition of oral bromocriptine to guideline-directed medical therapy improve left ventricular ejection fraction at 6 months and event-free survival compared to placebo in women with peripartum cardiomyopathy?
Answers are grounded in this paper and cite their sources.
The ongoing REBIRTH trial will be the first randomized controlled trial in a diverse North American cohort to determine whether adding bromocriptine to standard heart failure therapy improves myocardial recovery and clinical outcomes in women with peripartum cardiomyopathy.
Background There is evidence suggesting that bromocriptine potentially improves outcomes among women with peripartum cardiomyopathy (PPCM); however, there is currently no randomized controlled trial comparing bromocriptine vs placebo on top of guideline-directed medical therapy (GDMT) in a diverse, multiethnic cohort in North America. Objectives The REBIRTH trial will enroll 200 women with PPCM to evaluate whether the addition of oral bromocriptine to GDMT is superior to placebo for improving myocardial function and event-free survival. In addition to the randomized trial, REBIRTH will enroll 50 women with PPCM excluded from randomization because of breastfeeding into an observational cohort. Methods The principal inclusion criteria are ≥18 years of age, within 5-months postpartum, and left ventricular ejection fraction (LVEF) ≤40%. The primary endpoint is LVEF at 6 months postrandomization. Secondary endpoints include LVEF at 12 months, survival free from major events (ie, death, heart transplantation, or implantation of a durable left ventricular assist device), and survival free from heart failure hospitalization for up to 3 years. Results The study is currently enrolling women in both the randomized trial and observational breastfeeding cohort. Primary results are expected to be reported in 2027. Conclusions REBIRTH will determine whether the addition of bromocriptine to GDMT for heart failure with reduced ejection fraction improves postpartum myocardial recovery and clinical outcomes in a diverse cohort of women with PPCM. (Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for PPCM [REBIRTH]; NCT05180773).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an RCT in Peripartum cardiomyopathy (PPCM) (n=250). Oral bromocriptine added to guideline-directed medical therapy (GDMT) vs. Placebo added to guideline-directed medical therapy (GDMT) was evaluated on Left ventricular ejection fraction (LVEF) at 6 months postrandomization. Oral bromocriptine added to GDMT vs placebo is being evaluated for superiority in 6-month LVEF among 200 women with PPCM (ongoing trial; results expected in 2027).
Synapse has enriched 10 related papers. Consider them for comparative context: